SenzaGen Stock

SenzaGen EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of SenzaGen (SENZA.ST) as of Aug 8, 2026 is -14.53. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -8.82 — a change of 64.80% (lower).

EV/EBIT

-14.53

YoY

64.80%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of SenzaGen is 2026 -14.53 . EV/EBIT (Enterprise Value to EBIT) of SenzaGen was 2025 -8.82 . It decreases by 64.80% lower compared to the previous year.

The SenzaGen EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
-8.20 base
Jan 1, 2020
-10.05 base
Jan 1, 2021
-7.06 base
Jan 1, 2022
-14.39 base
Jan 1, 2023
-11.91 base
Jan 1, 2024
-10.74 base
Jan 1, 2025
-15.60 base
Jan 1, 2026 (e)
-3.27 base
YEARPRICE-TO-EBIT
2026 est -3.27
2025 -15.60
2024 -10.74
2023 -11.91
2022 -14.39
2021 -7.06
2020 -10.05
2019 -8.20
2018 -23.79
2017 -30.91
2016 -
2015 -
2014 -
Access this data via the Eulerpool API

SenzaGen Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides SenzaGen's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates SenzaGen's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots SenzaGen's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if SenzaGen grows earnings faster than its peers.

SenzaGen Stock analysis

What does SenzaGen do? SenzaGen AB is a Swedish biotechnology company that specializes in the development and marketing of innovative and reliable tests for assessing allergenicity. Founded in 2010 by leading experts from the academic and industry sectors, the company has become a significant player in the field of toxicology. Current methods for assessing allergenicity, such as asthma, eczema, and allergic reactions, are often inaccurate and require the use of animals, which is ethically questionable and expensive. SenzaGen AB has developed a wide range of tests based on biomolecular technologies that use human cells to assess the allergenic reactivity of chemicals and products. These tests are accurate, cost-effective, and meet the current requirements of regulatory authorities and the industry. The company is headquartered in Lund, Sweden, and currently employs about 20 people. SenzaGen AB is a leader in the development of in vitro methods for evaluating allergenicity and utilizes various platform technologies such as gene expression and proteomics analysis, as well as the use of immune cells and keratinocytes. SenzaGen AB's Microarray technology platform, based on DNA-based tests, has been recognized by the European Chemicals Agency (ECHA) as suitable for assessing allergenic reactivity. The company has also partnered with the US biotechnology company In vitro International (IVI) to distribute its allergen tests in the North American market. SenzaGen AB has developed a wide range of products that can be used in various sectors such as cosmetics, food, chemicals, and pharmaceuticals. AllergoDx™ is a test system used by the pharmaceutical and chemical industries to determine the allergenic reactivity of chemicals. GARD™ (Genomic Allergen Rapid Detection) is a rapid test used in the cosmetics and food industries to determine the allergenic reactivity of new products and avoid costly animal testing. GARDskin™ is a skin test used to determine the reactivity of substances that come into contact with the skin, primarily in the chemicals and pharmaceutical industries. Other products in the company's pipeline include GARDpotency™ and GARDair™, which are intended for assessing allergic reactions in industrial and occupational environments. SenzaGen AB has experienced significant growth in recent years and plans to expand its product range and strengthen its market position. The company's business model is based on selling tests and services to chemical, pharmaceutical, food, and cosmetic companies worldwide. Through its innovative technologies and willingness to collaborate with customers, the company has taken a leadership role in toxicology. SenzaGen AB is committed to an ethical and responsible corporate philosophy focused on sustainability and environmental protection. The company has clear goals to meet the growing demand for reliable and ethical testing methods to minimize the impact of chemicals on humans and the environment. SenzaGen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SenzaGen stock

EV/EBIT (Enterprise Value to EBIT) of SenzaGen is -14.53 in 2026.

EV/EBIT (Enterprise Value to EBIT) of SenzaGen changed from -8.82 to -14.53, representing a 64.80% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) SenzaGen since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s SenzaGen with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — SenzaGen

All Key Metrics — SenzaGen